Pozen's Wagon is Tied to Horizon and Sanofi

Horizon's (HZNP) purchase of AstraZeneca's (AZN) rights to Pozen's VImovo and Sanofi's bet on Pozen's cardiovascular drug have big implications for Pozen's future.

Feb 21, 2014 at 2:30PM

Sometimes collaboration deals with big pharmaceutical companies don't work out, and that was the case with Pozen's (NASDAQ:POZN)once-lucrative partnership with AstraZeneca (NYSE:AZN)The two teamed up to develop arthritis drug Vimovo in 2006, but sales have been elusive since the compound won FDA approval in 2010.

However, that may change given Astra sold its interest in Vimovo to Horizon (NASDAQ:HZNP)in November. Pozen hopes the shift to a more willing partner means Vimovo may finally fulfill its promise. If not, then Pozen's chances for success rest squarely on a recently inked deal with Sanofi (NYSE:SNY) instead.

POZN Chart

POZN data by YCharts

Resurrecting Vimovo
Between 2009 and 2011, Astra paid Pozen more than $50 million in milestones tied to Vimovo global filings and approvals. Yet, despite those payments Astra announced last March it was walking away from marketing the drug as part of major restructuring. As a result, royalties paid to Pozen by Astra totaled just $4.6 million through the first nine months of 2013.

That means the bar has been set pretty low for Horizon. The company paid Astra $35 million for the rights to Vimovo in hopes it can substantially boost sales by leveraging its existing rheumatology sales force.  

While Horizon only recently closed on the acquisition, early results are encouraging. In January, Horizon reported Vimovo prescriptions improved 4% month-over-month in December.

That's good news for Pozen shareholders given Pozen will receive a 10% royalty on any of Vimovo's U.S. sales, or a minimum royalty payment of $5 million in 2014, and $7.5 million annually until generics reach the market.

Sanofi takes a chance
Much like Vimovo, which combined the NSAID Naproxen with a protein pump inhibitor to limit ulcers in arthritis patients, Pozen's PA drugs combine aspirin with a protein pump inhibitor to limit ulcers in cardiovascular patients.

Despite Vimovo's inability to capture market share, Sanofi still agreed to pay Pozen $15 million upfront last fall to team up on PA8140 and PA32540 in the United States. Pozen has already filed both compounds with the FDA for approval.

If approved, the two drugs may find a willing market. NSAIDs are often prescribed to prevent clotting and reduce the risk of heart attack and stroke. However, patients on aspirin therapy have up to a five-fold chance of getting peptic ulcers, which require additional treatment including proton pump inhibitors, antihistamines, and sometimes antibiotics.

More than 300,000 people are hospitalized each year for upper GI bleeding costing roughly $2.5 billion a year. Of those admissions, peptic ulcers account for about 60% of all cases, suggesting an opportunity for Sanofi and Pozen.

For this reason, Sanofi has also agreed to pay up to $20 million in additional milestones tied to the approval of the PA drugs, as well as a 12.5% to 22.5% royalty on sales.

Fool-worthy final thoughts
Bigger royalty payments for Vimovo would be welcome, but such payments hinge entirely on Horizon's sales team. That means Pozen investors should be watching Horizon closely for cues as to whether Vimovo is gaining ground or flat-lining. 

It's similarly tough to gauge the potential impact of the Sanofi deal on Pozen given the PA drugs work similarly to Vimovo and have yet to win approval. Investors will need to watch the FDA closely on April 25th, the day they're scheduled to make a decision

If Pozen does get approval for those compounds, a partnership with a company for overseas rights will probably come soon after. However, since Pozen's fate rests on companies other than itself, it remains a highly speculative investment.

This company may prove a better buy
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.


Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers